John R. Moore - Aug 3, 2022 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Signature
/s/ John R. Moore
Stock symbol
EWTX
Transactions as of
Aug 3, 2022
Transactions value $
-$73,596
Form type
4
Date filed
8/5/2022, 04:12 PM
Previous filing
Jul 7, 2022
Next filing
Aug 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $9.13K +4.73K +157.67% $1.93 7.73K Aug 3, 2022 Direct F1
transaction EWTX Common Stock Options Exercise $3.2K +4.5K +58.24% $0.71* 12.2K Aug 3, 2022 Direct
transaction EWTX Common Stock Sale -$85.9K -9.23K -75.47% $9.31 3K Aug 3, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -4.73K -3.45% $0.00 132K Aug 3, 2022 Common Stock 4.73K $1.93 Direct F3
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -4.5K -3.85% $0.00 113K Aug 3, 2022 Common Stock 4.5K $0.71 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.07 to $9.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date.
F4 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.